Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap)  (beta) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer) Overgo Probe Designer
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:gefitinib
go back to main search page
Accession:CHEBI:49668 term browser browse the term
Definition:A member of the class of quinazolines that is quinazoline which is substituted by a (3-chloro-4-fluorophenyl)nitrilo group, 3-(morpholin-4-yl)propoxy group and a methoxy group at positions 4,6 and 7, respectively. An EGFR kinase inhibitor used for the treatment of non-small cell lung cancer.
Synonyms:exact_synonym: N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
 related_synonym: 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline;   Formula=C22H24ClFN4O3;   InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27);   InChIKey=XGALLCVXEZPNRQ-UHFFFAOYSA-N;   Iressa;   Irressat;   N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine;   SMILES=C1=C(C(=CC=2C1=NC=NC2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4)OC;   ZD 1839;   ZD1839;   gefitinibum
 alt_id: CHEBI:38917;   CHEBI:49667
 xref: CAS:184475-35-2;   DrugBank:DB00317;   Drug_Central:1282;   HMDB:HMDB0014462;   KEGG:D01977;   LINCS:LSM-1098
 xref_mesh: MESH:C419708
 xref: PDBeChem:IRE;   PMID:14981586;   PMID:15068398;   PMID:20573926;   PMID:20949670;   PMID:27396387;   PMID:28968167;   PMID:29332330;   PMID:29493460;   PMID:29579334;   PMID:29668619;   PMID:30068310;   PMID:30069771;   PMID:30214852;   Reaxys:8949523;   Wikipedia:Gefitinib


show annotations for term's descendants           Sort by:
gefitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO gefitinib results in decreased activity of ABCB11 protein CTD PMID:20829430 PMID:23956101 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [[gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; gefitinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Doxorubicin] CTD PMID:17938326 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions
decreases expression		 ISO [Gefitinib co-treated with CCL2 protein] results in increased expression of ACTA2 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of ACTA2 protein
Gefitinib results in decreased expression of ACTA2 protein		 CTD PMID:33248157 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Adora1 adenosine A1 receptor decreases expression ISO gefitinib results in decreased expression of ADORA1 mRNA CTD PMID:16685379 NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases expression		 ISO
EXP		 Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of AKT1 protein]
Gefitinib results in decreased expression of AKT1 mRNA
Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of AKT1 protein]		 CTD PMID:17805209 PMID:19233551 PMID:23255615 PMID:23948867 PMID:24568969 More... NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Ar androgen receptor multiple interactions ISO Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]] CTD PMID:29383186 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925 		JBrowse link
G Areg amphiregulin decreases response to substance
multiple interactions
affects response to substance		 ISO AREG protein results in decreased susceptibility to gefitinib
Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased expression of AREG mRNA]; Gefitinib inhibits the reaction [Irinotecan results in increased expression of AREG mRNA]
AREG protein affects the susceptibility to gefitinib		 CTD PMID:15496427 PMID:15723263 PMID:16230376 PMID:18980991 PMID:21258428 NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535 		JBrowse link
G Atg5 autophagy related 5 increases expression ISO gefitinib results in increased expression of ATG5 protein CTD PMID:21655094 NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Atg7 autophagy related 7 increases expression ISO gefitinib results in increased expression of ATG7 protein CTD PMID:21655094 NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593 		JBrowse link
G Aurka aurora kinase A decreases response to substance
multiple interactions		 ISO AURKA results in decreased susceptibility to gefitinib
[AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to Gefitinib; [TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib		 CTD PMID:21216229 NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390 		JBrowse link
G Aven apoptosis and caspase activation inhibitor affects response to substance ISO AVEN protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 3:99,299,009...99,431,635
Ensembl chr 3:99,298,930...99,431,634 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression EXP Gefitinib results in increased expression of BAX mRNA; Gefitinib results in increased expression of BAX protein CTD PMID:32370496 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2l11 Bcl2-like 11 increases response to substance ISO BCL2L11 protein results in increased susceptibility to gefitinib CTD PMID:20237869 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases expression
multiple interactions
decreases expression		 ISO gefitinib results in increased expression of BIRC5 protein
leptomycin B promotes the reaction [Gefitinib results in decreased expression of BIRC5 protein]; tyrphostin AG 1024 inhibits the reaction [Gefitinib results in increased expression of BIRC5 protein]
gefitinib results in decreased expression of BIRC5 protein		 CTD PMID:17473213 PMID:28942004 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] CTD PMID:25981168 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359 		JBrowse link
G Casp1 caspase 1 increases activity
multiple interactions		 ISO Gefitinib metabolite results in increased activity of CASP1 protein
N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [Gefitinib metabolite results in increased activity of CASP1 protein]		 CTD PMID:33132241 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383 		JBrowse link
G Casp3 caspase 3 increases expression
multiple interactions		 EXP
ISO		 gefitinib results in increased expression of CASP3 mRNA; gefitinib results in increased expression of CASP3 protein
[Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of CASP3 protein modified form]
EGFR gene mutant form promotes the reaction [gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; gefitinib results in increased cleavage of and results in increased activity of CASP3 protein		 CTD PMID:23523951 PMID:27084042 PMID:27639429 PMID:33248157 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 increases cleavage ISO Gefitinib results in increased cleavage of CASP8 protein CTD PMID:31168030 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Cav1 caveolin 1 increases expression ISO gefitinib results in increased expression of CAV1 mRNA; gefitinib results in increased expression of CAV1 protein CTD PMID:19288272 NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases secretion
multiple interactions
increases expression		 ISO Gefitinib results in increased secretion of CCL2 protein
[Gefitinib co-treated with CCL2 protein] results in increased expression of ACTA2 protein; [Gefitinib co-treated with CCL2 protein] results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of CASP3 protein modified form]; [Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of PARP1 protein modified form]; [Gefitinib results in increased secretion of CCL2 protein] which results in decreased expression of CDH1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of ACTA2 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of FN1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of VIM protein; cucurbitacin B inhibits the reaction [Gefitinib results in increased expression of CCL2 mRNA]		 CTD PMID:33248157 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO Gefitinib results in decreased expression of and affects the localization of CCNB1 protein CTD PMID:33548356 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions		 ISO gefitinib results in decreased expression of CCND1 protein
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 protein]		 CTD PMID:16740687 PMID:17513607 PMID:23948867 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccnd3 cyclin D3 decreases expression ISO gefitinib results in decreased expression of CCND3 protein CTD PMID:16740687 NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371 		JBrowse link
G Cd14 CD14 molecule multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]]; [gefitinib promotes the reaction arsenic trioxide] which results in increased expression of CD14 mRNA; gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]; SB 203580 inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]] CTD PMID:20226526 NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261 		JBrowse link
G Cdh1 cadherin 1 increases expression
multiple interactions		 ISO Gefitinib results in increased expression of CDH1 protein
[Gefitinib results in increased secretion of CCL2 protein] which results in decreased expression of CDH1 protein		 CTD PMID:33248157 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 increases phosphorylation ISO Gefitinib results in increased phosphorylation of CDK1 protein CTD PMID:33548356 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 decreases expression
multiple interactions		 ISO Gefitinib results in decreased expression of CDK6 protein
Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of CDK6 protein]		 CTD PMID:30136359 NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
decreases expression
multiple interactions		 ISO gefitinib results in increased expression of CDKN1A protein
gefitinib results in decreased expression of CDKN1A protein
leptomycin B inhibits the reaction [gefitinib results in decreased expression of CDKN1A protein]		 CTD PMID:17513607 PMID:28942004 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
decreases expression
increases expression		 ISO gefitinib promotes the reaction [[zoledronic acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of CDKN1B protein]
gefitinib results in decreased expression of CDKN1B
gefitinib results in increased expression of CDKN1B protein		 CTD PMID:14679152 PMID:16322342 PMID:16740687 PMID:17513607 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Cdkn2b cyclin-dependent kinase inhibitor 2B increases expression ISO gefitinib results in increased expression of CDKN2B mRNA; gefitinib results in increased expression of CDKN2B protein CTD PMID:17513607 NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050 		JBrowse link
G Cert1 ceramide transporter 1 affects response to substance ISO CERT1 protein affects the susceptibility to Gefitinib CTD PMID:15496427 NCBI chr 2:27,882,546...27,987,090
Ensembl chr 2:27,882,555...27,987,074 		JBrowse link
G Cgrrf1 cell growth regulator with ring finger domain 1 increases expression ISO gefitinib results in increased expression of CGRRF1 mRNA CTD PMID:16685379 NCBI chr15:20,088,564...20,109,042
Ensembl chr15:20,088,571...20,109,037 		JBrowse link
G Cldn2 claudin 2 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of CLDN2 mRNA CTD PMID:20935109 NCBI chr  X:103,459,870...103,473,794
Ensembl chr  X:103,459,780...103,474,838 		JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression
multiple interactions		 ISO Gefitinib results in decreased expression of COL1A1 protein
[Gefitinib co-treated with CCL2 protein] results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of COL1A1 protein		 CTD PMID:33248157 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Coro1c coronin 1C affects response to substance ISO CORO1C protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr12:42,712,960...42,785,179
Ensembl chr12:42,712,991...42,785,179 		JBrowse link
G Cycs cytochrome c, somatic affects localization ISO gefitinib affects the localization of CYCS protein CTD PMID:23523951 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases response to substance
increases expression
decreases activity		 ISO
EXP		 CYP1A1 protein results in increased susceptibility to gefitinib
Gefitinib results in increased expression of CYP1A1 mRNA
Gefitinib results in decreased activity of CYP1A1 protein		 CTD PMID:28652202 PMID:32370496 PMID:33814510 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO Gefitinib results in decreased activity of CYP1B1 protein CTD PMID:33814510 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects metabolic processing ISO CYP2D6 protein affects the metabolism of Gefitinib; CYP2D6 protein polymorphism affects the metabolism of Gefitinib CTD PMID:15788367 PMID:34936353 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp2f4 cytochrome P450, family 2, subfamily f, polypeptide 4 decreases expression ISO gefitinib results in decreased expression of CYP2F1 mRNA CTD PMID:16685379 NCBI chr 1:82,416,108...82,429,897
Ensembl chr 1:82,416,130...82,429,896 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 affects metabolic processing ISO CYP3A4 protein affects the metabolism of Gefitinib CTD PMID:15788367 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 affects metabolic processing ISO CYP3A5 protein affects the metabolism of gefitinib CTD PMID:15788367 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 increases secretion ISO Gefitinib metabolite results in increased secretion of DNAJB1 protein CTD PMID:33132241 NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458 		JBrowse link
G Dusp3 dual specificity phosphatase 3 affects response to substance ISO DUSP3 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962 		JBrowse link
G Dusp9 dual specificity phosphatase 9 decreases expression ISO gefitinib results in decreased expression of DUSP9 mRNA CTD PMID:16685379 NCBI chr  X:151,351,897...151,355,822
Ensembl chr  X:151,351,897...151,355,821 		JBrowse link
G E2f1 E2F transcription factor 1 decreases expression ISO gefitinib results in decreased expression of E2F1 mRNA; gefitinib results in decreased expression of E2F1 protein CTD PMID:17094457 PMID:18347146 NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361 		JBrowse link
G Ednrb endothelin receptor type B multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA] CTD PMID:18424623 NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]
gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]		 CTD PMID:15841081 PMID:16243822 PMID:17805209 PMID:17898861 PMID:18927496 More... NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064 		JBrowse link
G Egfr epidermal growth factor receptor decreases response to substance
affects response to substance
increases response to substance
multiple interactions
decreases expression
decreases phosphorylation
decreases activity		 ISO
EXP		 EGFR gene mutant form results in decreased susceptibility to Gefitinib; EGFR protein mutant form results in decreased susceptibility to Gefitinib
EGFR gene mutant form affects the susceptibility to Gefitinib; EGFR protein affects the susceptibility to Gefitinib; EGFR protein mutant form affects the susceptibility to Gefitinib
EGFR gene mutant form results in increased susceptibility to gefitinib; EGFR gene polymorphism results in increased susceptibility to gefitinib; EGFR protein mutant form results in increased susceptibility to gefitinib
[[Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [Gefitinib co-treated with betulin] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [Gefitinib co-treated with Oxaliplatin] results in decreased phosphorylation of EGFR protein; [Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]] which results in decreased activity of EGFR protein; [Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to Gefitinib; Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of EGFR protein modified form]; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein]; EGFR gene mutant form promotes the reaction [Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGFR protein results in decreased susceptibility to Docetaxel]; Gefitinib inhibits the reaction [Gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of EGFR protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]; Gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of EGFR protein; KRAS protein affects the reaction [EGFR protein affects the susceptibility to Gefitinib]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]
[Gefitinib results in decreased activity of EGFR protein] which results in increased susceptibility to naphthalene; Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of EGFR protein]; Gefitinib results in decreased phosphorylation of and results in decreased activity of EGFR protein
gefitinib results in decreased expression of EGFR protein modified form
gefitinib results in decreased phosphorylation of EGFR protein
Gefitinib results in decreased phosphorylation of EGFR protein
gefitinib results in decreased activity of EGFR protein
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]		 CTD PMID:13680161 PMID:14679152 PMID:15660382 PMID:15723263 PMID:15841081 More... NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Epor erythropoietin receptor increases expression ISO gefitinib results in increased expression of EPOR mRNA CTD PMID:16685379 NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257 		JBrowse link
G Eps15 epidermal growth factor receptor pathway substrate 15 increases expression ISO gefitinib results in increased expression of EPS15 mRNA CTD PMID:16685379 NCBI chr 5:124,045,865...124,146,221
Ensembl chr 5:124,045,926...124,146,221 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases phosphorylation		 ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]
gefitinib results in decreased phosphorylation of ERBB2 protein		 CTD PMID:16243822 PMID:17898861 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078 		JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
affects response to substance		 ISO ERCC1 gene polymorphism affects the susceptibility to [gefitinib co-treated with Cisplatin]
ERCC1 gene polymorphism affects the susceptibility to gefitinib		 CTD PMID:21264830 NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963 		JBrowse link
G Esr1 estrogen receptor 1 decreases phosphorylation ISO gefitinib results in decreased phosphorylation of ESR1 protein CTD PMID:16261397 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G Esr2 estrogen receptor 2 increases expression
multiple interactions		 ISO gefitinib results in increased expression of ESR2 protein
Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]		 CTD PMID:20005069 PMID:29383186 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919 		JBrowse link
G Faslg Fas ligand multiple interactions
increases response to substance		 ISO benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Gefitinib results in increased susceptibility to FASLG protein] CTD PMID:31168030 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215 		JBrowse link
G Fgf6 fibroblast growth factor 6 increases expression ISO gefitinib results in increased expression of FGF6 mRNA CTD PMID:16685379 NCBI chr 4:159,854,913...159,863,447
Ensembl chr 4:159,854,913...159,863,447 		JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of FN1 protein CTD PMID:33248157 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678 		JBrowse link
G Foxf1 forkhead box F1 multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA] CTD PMID:18424623 NCBI chr19:49,153,729...49,157,741
Ensembl chr19:49,153,699...49,157,738 		JBrowse link
G Foxo3 forkhead box O3 increases response to substance
multiple interactions
increases expression		 ISO
EXP		 FOXO3 protein results in increased susceptibility to gefitinib
gefitinib results in decreased phosphorylation of and affects the localization of FOXO3 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of FOXO3 mRNA]
Gefitinib results in increased expression of FOXO3 mRNA; Gefitinib results in increased expression of FOXO3 protein; Gefitinib results in increased expression of FOXO3 protein modified form		 CTD PMID:18089711 PMID:32370496 NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression ISO gefitinib results in increased expression of GADD45A mRNA CTD PMID:16685379 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115 		JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma decreases expression ISO gefitinib results in decreased expression of GADD45G mRNA CTD PMID:16685379 NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610 		JBrowse link
G Gars1 glycyl-tRNA synthetase 1 increases expression ISO Gefitinib results in increased expression of GARS1 mRNA CTD PMID:16685379 NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit affects response to substance ISO GCLC protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions EXP gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]] CTD PMID:29228391 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589 		JBrowse link
G Gnb2 G protein subunit beta 2 decreases expression ISO gefitinib results in decreased expression of GNB2 mRNA CTD PMID:16685379 NCBI chr12:19,159,002...19,164,021
Ensembl chr12:19,158,973...19,164,019 		JBrowse link
G Gnmt glycine N-methyltransferase multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of GNMT mRNA CTD PMID:20935109 NCBI chr 9:14,254,675...14,258,028
Ensembl chr 9:14,254,675...14,258,434 		JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO Gefitinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases expression ISO Gefitinib results in decreased expression of GSK3B protein modified form CTD PMID:30136359 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Gucy2d guanylate cyclase 2D, retinal decreases expression ISO gefitinib results in decreased expression of GUCY2D mRNA CTD PMID:16685379 NCBI chr10:53,954,918...53,975,576
Ensembl chr10:53,959,010...53,974,067 		JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO Gefitinib promotes the reaction [Folic Acid results in increased expression of HAVCR1 protein] CTD PMID:23255615 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698 		JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO
EXP		 gefitinib inhibits the reaction [irinotecan metabolite results in increased expression of HBEGF mRNA]; gefitinib inhibits the reaction [irinotecan results in increased expression of HBEGF mRNA]
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased secretion of HBEGF protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]		 CTD PMID:15723263 PMID:29228391 NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of HIF1A protein] CTD PMID:21544845 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hmgb1 high mobility group box 1 increases secretion ISO Gefitinib metabolite results in increased secretion of HMGB1 protein CTD PMID:33132241 NCBI chr12:5,973,062...5,978,565
Ensembl chr12:5,901,586...5,978,565 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions		 EXP
ISO		 gefitinib results in increased expression of HMOX1 mRNA; gefitinib results in increased expression of HMOX1 protein
[Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of HMOX1 mRNA		 CTD PMID:27084042 PMID:32741899 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 increases secretion ISO Gefitinib metabolite results in increased secretion of HSP90AA1 protein CTD PMID:33132241 NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268 		JBrowse link
G Hspa1b heat shock protein family A (Hsp70) member 1B increases secretion ISO Gefitinib metabolite results in increased secretion of HSPA1A protein CTD PMID:33132241 NCBI chr20:3,870,765...3,873,221 JBrowse link
G Igf1r insulin-like growth factor 1 receptor multiple interactions
increases phosphorylation		 ISO gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; tyrphostin AG 1024 inhibits the reaction [gefitinib results in increased phosphorylation of IGF1R protein] CTD PMID:17473213 NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression		 ISO gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B protein]
Gefitinib metabolite results in increased expression of IL1B protein		 CTD PMID:23948867 PMID:33132241 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Itgam integrin subunit alpha M multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein]]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM mRNA]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein] CTD PMID:20226526 NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503 		JBrowse link
G Itgav integrin subunit alpha V multiple interactions ISO gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA] CTD PMID:15841081 NCBI chr 3:68,838,524...68,926,653
Ensembl chr 3:68,838,189...68,926,639 		JBrowse link
G Itgb1 integrin subunit beta 1 multiple interactions ISO [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to gefitinib CTD PMID:21478906 NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195 		JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA] CTD PMID:18424623 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 increases expression ISO gefitinib results in increased expression of KEAP1 mRNA CTD PMID:27639429 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862 		JBrowse link
G Kras KRAS proto-oncogene, GTPase affects response to substance
multiple interactions
decreases response to substance		 ISO KRAS protein mutant form affects the susceptibility to gefitinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to gefitinib]
KRAS protein results in decreased susceptibility to gefitinib		 CTD PMID:17270025 PMID:28739874 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Lcn2 lipocalin 2 multiple interactions ISO Gefitinib promotes the reaction [Folic Acid results in increased expression of LCN2 protein] CTD PMID:23255615 NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095 		JBrowse link
G Lepr leptin receptor decreases expression ISO gefitinib results in decreased expression of LEPR mRNA CTD PMID:16685379 NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908 		JBrowse link
G Lgals9 galectin 9 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of LGALS9 mRNA CTD PMID:20935109 NCBI chr10:63,907,018...63,930,224
Ensembl chr10:63,907,018...63,930,045 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases expression
decreases phosphorylation
increases phosphorylation		 ISO
EXP		 Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK1 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK1 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK1 protein]
gefitinib results in decreased expression of MAPK1 protein modified form
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK1 protein]
gefitinib results in increased phosphorylation of MAPK1 protein		 CTD PMID:15660382 PMID:16322342 PMID:17145836 PMID:17805209 PMID:17898861 More... NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
decreases expression
increases phosphorylation		 ISO
EXP		 Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK3 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK3 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK3 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK3 protein]
gefitinib results in decreased expression of MAPK3 protein modified form
gefitinib results in increased phosphorylation of MAPK3 protein
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK3 protein]		 CTD PMID:15660382 PMID:16322342 PMID:17145836 PMID:17805209 PMID:17898861 More... NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation
decreases phosphorylation		 ISO gefitinib results in increased phosphorylation of MAPK8 protein
Gefitinib results in decreased phosphorylation of MAPK8 protein		 CTD PMID:20846305 PMID:35317323 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Marveld1 MARVEL domain containing 1 decreases response to substance ISO MARVELD1 protein results in decreased susceptibility to Gefitinib CTD PMID:27447558 NCBI chr 1:240,954,452...240,958,384
NCBI chr 1:240,953,889...240,958,096
Ensembl chr 1:240,954,452...240,958,384 		JBrowse link
G Mdk midkine multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA] CTD PMID:18424623 NCBI chr 3:77,901,156...77,903,997
Ensembl chr 3:77,901,158...77,903,130 		JBrowse link
G Micb MHC class I polypeptide-related sequence B increases expression ISO Gefitinib results in increased expression of MICB protein CTD PMID:21951556 NCBI chr 1:78,495,779...78,513,030
Ensembl chr 1:78,495,779...78,512,827 		JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [Gefitinib co-treated with betulin] results in decreased expression of MKI67 protein CTD PMID:27447558 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762 		JBrowse link
G Mlh1 mutL homolog 1 decreases expression ISO gefitinib results in decreased expression of MLH1 mRNA CTD PMID:16685379 NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
decreases expression		 ISO
EXP		 gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]
gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]
Gefitinib results in decreased expression of MMP9 mRNA; Gefitinib results in decreased expression of MMP9 protein		 CTD PMID:15841081 PMID:23127547 PMID:27087131 PMID:29228391 PMID:35317323 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mr1 major histocompatibility complex, class I-related affects expression ISO gefitinib affects the expression of MR1 mRNA CTD PMID:25811541 NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970 		JBrowse link
G Mt2A metallothionein 2A multiple interactions ISO [Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of MT2 mRNA CTD PMID:32741899 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784 		JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases phosphorylation ISO gefitinib results in decreased phosphorylation of MTOR protein CTD PMID:21655094 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC mRNA]; gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC protein] CTD PMID:21544845 NCBI chr 1:196,864,375...196,896,475
Ensembl chr 1:196,864,336...196,896,475 		JBrowse link
G Mug1 murinoglobulin 1 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of MUG1 mRNA CTD PMID:20935109 NCBI chr 4:155,076,270...155,130,051
Ensembl chr 4:155,076,312...155,130,051 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO gefitinib results in decreased expression of MYC protein CTD PMID:17513607 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Myh7 myosin heavy chain 7 increases expression EXP gefitinib results in increased expression of MYH7 mRNA; gefitinib results in increased expression of MYH7 protein CTD PMID:27084042 NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217 		JBrowse link
G Ndufaf4 NADH:ubiquinone oxidoreductase complex assembly factor 4 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of NDUFAF4 mRNA CTD PMID:20935109 NCBI chr 5:38,605,169...38,610,341
Ensembl chr 5:38,605,153...38,610,336 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 decreases expression ISO gefitinib results in decreased expression of NFKB1 mRNA CTD PMID:16685379 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO [AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to gefitinib CTD PMID:21216229 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nppa natriuretic peptide A multiple interactions
increases expression		 EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of NPPA mRNA]
Gefitinib results in increased expression of NPPA mRNA; Gefitinib results in increased expression of NPPA protein		 CTD PMID:32370496 NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351 		JBrowse link
G Nppb natriuretic peptide B increases expression EXP gefitinib results in increased expression of NPPB mRNA; gefitinib results in increased expression of NPPB protein CTD PMID:27084042 NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168 		JBrowse link
G Nptx2 neuronal pentraxin 2 decreases expression ISO gefitinib results in decreased expression of NPTX2 mRNA CTD PMID:16685379 NCBI chr12:10,037,435...10,048,345
Ensembl chr12:10,037,435...10,048,345 		JBrowse link
G Nrl neural retina leucine zipper decreases expression ISO gefitinib results in decreased expression of NRL mRNA CTD PMID:16685379 NCBI chr15:29,008,104...29,009,832
Ensembl chr15:29,008,104...29,009,832 		JBrowse link
G Osmr oncostatin M receptor affects response to substance ISO OSMR protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 2:55,907,119...55,961,373
Ensembl chr 2:55,907,132...55,961,262 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
increases expression		 ISO Betulinic Acid promotes the reaction [Gefitinib results in increased cleavage of PARP1 protein]; Gefitinib affects the reaction [Oxaliplatin results in increased cleavage of PARP1 protein]
gefitinib results in increased cleavage of PARP1 protein
[Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of PARP1 protein modified form]		 CTD PMID:16243822 PMID:23523951 PMID:30136359 PMID:33248157 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO Gefitinib inhibits the reaction [Folic Acid results in increased expression of PCNA protein] CTD PMID:23255615 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995 		JBrowse link
G Pcnt pericentrin decreases response to substance ISO PCNT protein results in decreased susceptibility to gefitinib CTD PMID:26298006 NCBI chr20:12,190,597...12,278,723
Ensembl chr20:12,191,648...12,278,710 		JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 multiple interactions
decreases expression		 ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA]
Gefitinib results in decreased expression of PECAM1 protein		 CTD PMID:18424623 PMID:35317323 NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116 		JBrowse link
G Pgrmc1 progesterone receptor membrane component 1 decreases response to substance ISO PGRMC1 protein results in decreased susceptibility to gefitinib CTD PMID:26298006 NCBI chr  X:115,832,865...115,841,060
Ensembl chr  X:115,832,884...115,888,682 		JBrowse link
G Phlda2 pleckstrin homology-like domain, family A, member 2 affects response to substance ISO PHLDA2 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 1:198,696,897...198,699,292
Ensembl chr 1:198,696,897...198,697,836 		JBrowse link
G Plau plasminogen activator, urokinase multiple interactions ISO gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]] CTD PMID:23127547 NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775 		JBrowse link
G Plbd1 phospholipase B domain containing 1 affects response to substance ISO PLBD1 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 4:169,472,983...169,529,277
Ensembl chr 4:169,472,983...169,529,277 		JBrowse link
G Pten phosphatase and tensin homolog multiple interactions
increases expression		 EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of PTEN mRNA]
Gefitinib results in increased expression of PTEN mRNA; Gefitinib results in increased expression of PTEN protein; Gefitinib results in increased expression of PTEN protein modified form		 CTD PMID:32370496 NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO gefitinib promotes the reaction [[zoledronic acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of PTGS2 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of PTGS2 protein]		 CTD PMID:16322342 PMID:23948867 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin multiple interactions
decreases response to substance		 ISO gefitinib results in decreased stability of and results in decreased expression of PTTG1 protein
PTTG1 protein results in decreased susceptibility to gefitinib		 CTD PMID:23523951 NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837 		JBrowse link
G Qsox1 quiescin sulfhydryl oxidase 1 increases expression ISO gefitinib results in increased expression of QSOX1 mRNA CTD PMID:16685379 NCBI chr13:67,949,780...67,987,434
Ensembl chr13:67,949,780...67,987,459 		JBrowse link
G Rad51 RAD51 recombinase affects response to substance ISO RAD51 protein affects the susceptibility to Gefitinib CTD PMID:34998818 NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035 		JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases expression
multiple interactions		 ISO Gefitinib results in decreased expression of RB1 protein modified form
Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of RB1 protein modified form]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form]		 CTD PMID:30136359 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Rbm7 RNA binding motif protein 7 affects response to substance ISO RBM7 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 8:48,831,894...48,838,399
Ensembl chr 8:48,831,894...48,838,411 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases response to substance		 ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]
RELA protein results in decreased susceptibility to gefitinib		 CTD PMID:19318490 PMID:21216229 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Rpa1 replication protein A1 increases expression ISO gefitinib results in increased expression of RPA1 mRNA CTD PMID:16685379 NCBI chr10:60,148,869...60,199,999
Ensembl chr10:60,148,793...60,199,949 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation ISO gefitinib results in decreased phosphorylation of RPS6KB1 protein CTD PMID:21655094 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908 		JBrowse link
G Rrm1 ribonucleotide reductase catalytic subunit M1 affects response to substance ISO RRM1 gene polymorphism affects the susceptibility to gefitinib CTD PMID:21264830 NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261 		JBrowse link
G RT1-CE5 RT1 class I, locus CE5 affects expression ISO gefitinib affects the expression of HLA-F mRNA CTD PMID:25811541 NCBI chr20:3,403,418...3,479,476 JBrowse link
G RT1-Db1 RT1 class II, locus Db1 affects expression ISO gefitinib affects the expression of HLA-DRB1 mRNA CTD PMID:25811541 NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258 		JBrowse link
G RT1-DOa RT1 class II, locus DOa affects expression ISO gefitinib affects the expression of HLA-DOA mRNA CTD PMID:25811541 NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577 		JBrowse link
G S100a6 S100 calcium binding protein A6 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of S100A6 mRNA CTD PMID:20935109 NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180 		JBrowse link
G S100a8 S100 calcium binding protein A8 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of S100A8 mRNA; [gefitinib co-treated with naphthalene] affects the expression of S100A8 protein CTD PMID:20935109 NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643 		JBrowse link
G Serpinf1 serpin family F member 1 multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA] CTD PMID:18424623 NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646 		JBrowse link
G Sfn stratifin decreases expression ISO gefitinib results in decreased expression of SFN mRNA CTD PMID:16685379 Ensembl chr 5:145,826,201...145,831,314 JBrowse link
G Ski Ski proto-oncogene increases expression ISO gefitinib results in increased expression of SKI mRNA CTD PMID:16685379 NCBI chr 5:165,713,525...165,782,134
Ensembl chr 5:165,714,093...165,782,733 		JBrowse link
G Slc10a3 solute carrier family 10, member 3 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of SLC10A3 mRNA CTD PMID:20935109 NCBI chr  X:152,154,757...152,158,563
Ensembl chr  X:152,151,076...152,162,958 		JBrowse link
G Snai2 snail family transcriptional repressor 2 affects response to substance ISO SNAI2 protein affects the susceptibility to gefitinib CTD PMID:21037017 NCBI chr11:86,183,800...86,186,109
Ensembl chr11:86,181,909...86,186,200 		JBrowse link
G Sox17 SRY-box transcription factor 17 decreases localization ISO gefitinib results in decreased localization of SOX17 protein CTD PMID:24154490 NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228 		JBrowse link
G Sqstm1 sequestosome 1 decreases expression
multiple interactions		 ISO Gefitinib results in decreased expression of SQSTM1 protein
[Gefitinib co-treated with Cisplatin] results in decreased expression of SQSTM1 protein; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein]		 CTD PMID:25979647 PMID:27639429 NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Gefitinib co-treated with betulin] results in decreased expression of SREBF1 protein CTD PMID:27447558 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of STAT3 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of STAT3 protein]		 CTD PMID:19318490 PMID:21787763 PMID:23948867 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Synpo synaptopodin multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of SYNPO mRNA CTD PMID:20935109 NCBI chr18:54,048,299...54,106,388
Ensembl chr18:54,026,152...54,102,126 		JBrowse link
G Tek TEK receptor tyrosine kinase multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA] CTD PMID:18424623 NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804 		JBrowse link
G Tert telomerase reverse transcriptase decreases expression ISO gefitinib results in decreased expression of TERT mRNA CTD PMID:17094457 NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561 		JBrowse link
G Tfap2a transcription factor AP-2 alpha multiple interactions ISO gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] CTD PMID:21499124 PMID:21951556 NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507 		JBrowse link
G Tgfa transforming growth factor alpha decreases response to substance
multiple interactions		 ISO TGFA protein results in decreased susceptibility to gefitinib
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; gefitinib inhibits the reaction [irinotecan metabolite results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [irinotecan results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]
gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA]		 CTD PMID:15723263 PMID:16230376 PMID:18424623 PMID:21266357 NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression		 ISO Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF mRNA]; Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF protein]; Gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA]; Gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
Gefitinib results in decreased expression of TNF mRNA
Gefitinib results in decreased expression of and results in decreased secretion of TNF protein		 CTD PMID:15841081 PMID:23948867 PMID:35317323 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfrsf1b TNF receptor superfamily member 1B decreases expression ISO gefitinib results in decreased expression of TNFRSF1B mRNA CTD PMID:16685379 NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206 		JBrowse link
G Tnni3 troponin I3, cardiac type increases secretion EXP Gefitinib results in increased secretion of TNNI3 protein CTD PMID:32370496 NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
affects response to substance
increases expression		 ISO
EXP		 [TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein]
TP53 protein affects the susceptibility to gefitinib
gefitinib results in increased expression of TP53 mRNA; gefitinib results in increased expression of TP53 protein		 CTD PMID:21216229 PMID:27084042 PMID:29383186 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Trim23 tripartite motif-containing 23 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of TRIM23 mRNA CTD PMID:20935109 NCBI chr 2:35,302,405...35,335,746
Ensembl chr 2:35,302,409...35,335,743 		JBrowse link
G Tsc22d1 TSC22 domain family, member 1 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of TSC22D1 mRNA CTD PMID:20935109 NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958 		JBrowse link
G Twist1 twist family bHLH transcription factor 1 affects response to substance ISO TWIST1 protein affects the susceptibility to Gefitinib CTD PMID:30993382 NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653 		JBrowse link
G Tyms thymidylate synthetase decreases expression
multiple interactions		 ISO Gefitinib results in decreased expression of TYMS mRNA; Gefitinib results in decreased expression of TYMS protein
Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of TYMS protein]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of TYMS protein]; TYMS protein affects the susceptibility to [Gefitinib co-treated with S 1 (combination)]		 CTD PMID:18347146 PMID:30136359 NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536 		JBrowse link
G Ulbp1 UL16 binding protein 1 increases expression
multiple interactions		 ISO Gefitinib results in increased expression of ULBP1 mRNA; Gefitinib results in increased expression of ULBP1 protein
Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib results in increased expression of ULBP1 mRNA]		 CTD PMID:21499124 PMID:21951556 NCBI chr 1:1,694,255...1,716,160 JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases expression		 ISO
EXP		 gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]
gefitinib results in decreased expression of VEGFA protein
Gefitinib results in decreased expression of VEGFA mRNA; Gefitinib results in decreased expression of VEGFA protein		 CTD PMID:15660382 PMID:18424623 PMID:35317323 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Vim vimentin multiple interactions ISO [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of VIM protein; Gefitinib inhibits the reaction [Folic Acid results in increased expression of VIM protein] CTD PMID:23255615 PMID:33248157 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187 		JBrowse link
G Xrcc1 X-ray repair cross complementing 1 affects response to substance ISO XRCC1 protein polymorphism affects the susceptibility to gefitinib CTD PMID:21264830 NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701 		JBrowse link
G Zc3h3 zinc finger CCCH type containing 3 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of ZC3H3 mRNA CTD PMID:20935109 NCBI chr 7:107,440,694...107,525,451
Ensembl chr 7:107,440,694...107,525,451 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19751
    role 19724
      application 19557
        pharmaceutical 19440
          drug 19440
            antineoplastic agent 17649
              gefitinib 163
                linkable gefitinib analogue 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19751
    subatomic particle 19749
      composite particle 19749
        hadron 19749
          baryon 19749
            nucleon 19749
              atomic nucleus 19749
                atom 19749
                  main group element atom 19698
                    main group molecular entity 19698
                      s-block molecular entity 19554
                        hydrogen molecular entity 19546
                          hydrides 19022
                            inorganic hydride 17950
                              pnictogen hydride 17936
                                nitrogen hydride 17835
                                  azane 17621
                                    ammonia 17620
                                      organic amino compound 17620
                                        secondary amino compound 6754
                                          gefitinib 163
                                            linkable gefitinib analogue 0
paths to the root